Cetuximab or bevacizumab in metastatic colorectal cancer?

Lancet Oncol. 2014 Sep;15(10):1040-1. doi: 10.1016/S1470-2045(14)70360-2. Epub 2014 Jul 31.

Authors

Francesco Sclafani¹, David Cunningham²

Affiliations

¹ Department of Medicine, The Royal Marsden NHS Foundation Trust Hospital, Sutton, Surrey, SM2 5PT, UK.
² Department of Medicine, The Royal Marsden NHS Foundation Trust Hospital, Sutton, Surrey, SM2 5PT, UK. Electronic address: david.cunningham@rmh.nhs.uk.

PMID: 25088941
DOI: 10.1016/S1470-2045(14)70360-2

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Camptothecin / analogs & derivatives*
Camptothecin / therapeutic use
Cetuximab
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology*
Female
Fluorouracil / therapeutic use
Humans
Leucovorin / therapeutic use
Male

Substances

Antibodies, Monoclonal, Humanized
Bevacizumab
Cetuximab
Leucovorin
Fluorouracil
Camptothecin

Supplementary concepts

IFL protocol